-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

636. Myelodysplastic Syndromes—Basic and Translational: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5, Level 1, Building B (Georgia World Congress Center)

Samuli Eldfors, PhD1,2,3, Sumit Rai, PhD1,2*, Vineet Sharma, PhD1,2*, Angelique N Gilbert1*, Kimmo Porkka, MD, PhD4,5* and Timothy A. Graubert, MD1,2

1Cancer Center, Massachusetts General Hospital, Charlestown, MA
2Harvard Medical School, Boston, MA
3Department of Medicine, University of Helsinki, Helsinki, Finland
4Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
5iCAN Digital Precision Cancer Center Medicine Flagship, University of Helsinki, Helsinki, Finland

Sunisa Kongkiatkamon, MD1,2*, Laila Terkawi3*, Vera Adema, PhD4*, Yihong Guan, PhD5*, Metis Hasipek, PhD6*, Tatiana Dombrovski7*, Milo Co8*, Wencke Walter, PhD9*, Cassandra M Kerr, MS5*, Yasunobu Nagata, MD, PhD8*, Hassan Awada, MD5, Yvonne Parker10*, Stephan Hutter, PhD9*, Simona Pagliuca, MD5, Carmelo Gurnari, MD5*, Manja Meggendorfer, PhD11, Daniel Lindner, MD, PhD10*, Valeria Visconte, PhD12, Torsten Haferlach, MD9, Thomas LaFramboise, Ph.D.7*, Babal K. Jha, PhD, MPhil, MSc, BSc5* and Jaroslaw P. Maciejewski, MD, PhD5

1Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
2Department of Translational and Hematology Research, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland Clinic, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, cleveland, OH
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
6Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
7Department of Genetics and Genome Sciences Case Western Reserve University School of Medicine, Cleveland, OH
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9MLL Munich Leukemia Laboratory, Munich, Germany
10Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland
11MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany
12Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

Joshua Xu1, Tony Chen, BSc2, Ava Keyvani Chahi, MSc2, Gabriela Krivdova, BSc3,4*, Sajid Marhon5*, Ana Vujovic6,7*, Nicholas Wong, PhD8*, John E. Dick, PhD9,10,11 and Kristin Hope, PhD2,6,7

1Department of Biochemistry and Biomedical Sciences, McMaster Stem Cell and Cancer Research Institute, Hamilton, ON, Canada
2Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
3Molecular Genetics, University of Toronto, Toronto, ON, Canada
4Princess Margaret Cancer Centre, University Health Network, Mississauga, ON, Canada
5University Health Network, Toronto, Canada
6Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
7Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
8Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
9Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
10University Health Network, Toronto, ON, Canada
11Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

Yue Wei, PhD1, Hong Zheng1*, Pamela Lockyer, MS1*, Naran Bao1*, Faezeh Darbaniyan, PhD2*, Ziyi Li, PhD2*, Rashmi Kanagal-Shamanna, MD3, Kelly A. Soltysiak, PhD1*, Hui Yang, MD, PhD1, Irene Ganan-Gomez, PhD1, Kim-Anh Do, PhD2*, Simona Colla, PhD1*, Kelly S. Chien, MD1, Guillermo Montalban-Bravo, MD1, Naval Daver, MD4 and Guillermo Garcia-Manero, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
4MD Anderson Cancer Center, Houston, TX

Carmelo Gurnari, MD1,2*, Simona Pagliuca, MD2, Yihong Guan, PhD2*, Courtney E. Hershberger, PhD3, Ying Ni, PhD4*, Jaymeson Gordon2*, Hetty E. Carraway, MD, MBA5, Richard A Padgett, PhD6*, Diego Coutinho7*, Ilana Zalcberg7*, Jae-Sook Ahn, MD, PhD8*, Hyeoung-Joon Kim, MD, PhD9, Dennis Dong Hwan Kim Sr., MD10, Mark D. Minden, MD, PhD10, Joop H. Jansen, PhD11, Babal K. Jha, PhD, MPhil, MSc, BSc2*, Torsten Haferlach, MD12, Jaroslaw P. Maciejewski, MD, PhD2 and Valeria Visconte, PhD13

1Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
4Center for Clinical Genomics, Cleveland Clinic Foundation, Cleveland, OH
5Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Foundation, Cleveland, OH
7Divisão de Laboratórios do Centro de Transplantes de Medula Óssea (CEMO), Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil
8Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun-Gun, Jeollanam-Do, South Korea
9Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of (South)
10Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
11Radboud Institute Molecular Studies, Radboud University Medical Center, Nijmegen, Netherlands
12MLL Munich Leukemia Laboratory, Munich, Germany
13Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

Tariq Kewan, MD1*, Arda Durmaz2*, Hassan Awada, MD3, Carmelo Gurnari, MD4,5*, Waled Bahaj, MD1*, Simona Pagliuca, MD1, Laila Terkawi6*, Ramsha Ahmed, MD7*, Suresh Kumar Balasubramanian, MD8, Bhumika J. Patel, MD9, Hetty E. Carraway, MD, MBA9, Valeria Visconte, PhD6, Torsten Haferlach, MD10 and Jaroslaw P. Maciejewski, MD, PhD1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Department of Systems biology and Bioinformatics, CWRU, cleveland
3Roswell Park Comprehensive Cancer Center, Buffalo, NY
4Department of Translational Hematology and Oncology Research, Taussig Cancer Ins, Cleveland, OH
5Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy
6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH
7Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
8Wayne State University, Detroit, MI
9Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
10MLL Munich Leukemia Laboratory, Munich, Germany

Tariq Kewan, MD1*, Hrishikesh M Mehta, PhD2, Carmelo Gurnari, MD3,4*, Waled Bahaj, MD1*, Simona Pagliuca, MD1, Suresh Kumar Balasubramanian, MD5, Bhumika J. Patel, MD6, Anjali Advani, MD7, Valeria Visconte, PhD8, Hetty E. Carraway, MD, MBA6, Seth J. Corey, MD, MPH9 and Jaroslaw P. Maciejewski, MD, PhD1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Cancer Biology, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Ins, Cleveland, OH
4Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy
5Karmanos Cancer Center, Detroit
6Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
7Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH
9Departments of Pediatrics and Cancer Biology, Cleveland Clinic, Cleveland, OH

Tong Xing1,2*, Zhong-Shi Lyu, PhD1,2*, Cai-Wen Duan3*, Qi Wen2*, Hong-Yan Zhao2*, Shu-Qian Tang2*, Yuan-Yuan Zhang2*, Meng Lv2*, Yu Wang2*, Lan-Ping Xu2*, Xiao-Hui Zhang2*, Xiao-Jun Huang1,2 and Yuan Kong2*

1Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
2Peking University People's Hospital, Beijing, China
3Shanghai Jiao-Tong University School of Medicine, Shanghai, China

Robert P Dalton III1*, Grace A Ward, BS1,2, Sean Christiansen1*, Alexandra Calescibetta1*, Elena Kostenko1*, Gabriela Wright3*, Jason M Foulks, PhD4*, Mathew Lalonde, PhD4*, Steven L. Warner, PhD4, Kenneth Wright, PhD1* and Erika A Eksioglu, PhD, MS1

1Immunology, Moffitt Cancer Center, Tampa, FL
2Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL
3Molecular Oncology, Moffitt Cancer Center, Tampa, FL
4Sumitomo Dainippon Pharma Oncology, Lehi, UT

Laura Hurtado-Navarro, PhD Student1*, Ernesto J Cuenca2,3*, Eva Soler, MD3*, Andres Jerez4,5*, Helios Martínez-Banaclocha, PhD6*, Esperanza Such, PhD7,8*, Beatriz Bellosillo, PhD9*, Lurdes Zamora, PhD10*, Jesus Maria Hernández-Rivas, MD PhD11,12,13, Javier Marco, MD14*, Laura Martínez-Alarcón, PhD15*, María Dolores Linares-Latorre, MD16*, Josefa Marco, MD PhD17*, Sara García Ávila, MD18,19,20*, Paula Amat, MD PhD21*, Teresa González, PhD22,23,24*, Marta Martín Izquierdo, MSc22*, Montserrat Arnan Sangerman, MD PhD25*, Helena Pomares26*, Tzu Hua Chen-Liang, MD PhD27*, Maite Herranz, MD PhD28*, Gonzalo Carreño, MD PhD29,30*, Carlos Garcia-Palenciano, MD PhD31*, Raul Teruel Montoya, PhD2,32*, Pablo Pelegrin, PhD33* and Francisca Ferrer Marin, MD PhD3,34,35*

1Línea de Inflamación Molecular, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
2CIBER Enfermedades raras CIBER-ER (CB15/00055), Murcia, Spain
3Unidad de Hematología y Oncología Médica. Hosp. Univ. Morales-Meseguer. Centro Regional de Hemodonación. Universidad de Murcia. IMIB-Arrixaca, Murcia, Spain
4Grupo Español de Síndromes Mielodisplásicos (GESMD), Valencia, Spain
5Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB, Murcia, Spain
6Molecular Inflammation Research Group, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB, Murcia, Spain
7CIBERONC, Madrid, Spain
8Hematology Department., Hospital Universitario y Politécnico La Fe, Valencia, Spain
9Pathology Department-IMIM, Universidad Pompeu Fabra, Hospital del Mar, Barcelona, Barcelona, ESP Group of Applied Clinical Research in Hematology. Cancer research program-IMIM, Barcelona, Spain
10Hematology Department, ICO - Hospital Germans Trias i Pujol, Badalona, Spain
11HARMONY Alliance Chair, Salamanca, Spain
12Complejo Asistencial Universitario de Salamanca Hospital Clínico, Salamanca, Spain
13IBSAL, IBMCC, CIC, Universidad de Salamanca-CSIC, Salamanca, Spain
14Servicio Hematologia Hospital La Fe, Valencia, Spain
15General Surgery Service, Virgen de la Arrixaca University Hospital, Instituto Murciano de Investigaciones Biosanitarias (IMIB), Murcia, Spain
16Departamento de Hematología, Instituto Valenciano de Oncología, Valencia, Spain
17Hospital Dr. Peset, Valencia, Spain
18Servei d’Hematologia Clinica, Hospital del Mar, Barcelona, Spain
19Grup de Recerca Clínica, Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM. Department of Hematology, Hospital del Mar., Barcelona, Spain
20Hematology Department, University Hospital "Marqués de Valdecilla", Santander, Spain
21Hematology Department, Servicio de Hematología, Hospital Clínico Universitario de Valencia, Valencia, Spain
22Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
23Servicio de Hematología Clínica, Hospital Universitario de Salamanca, Salamanca, Salamanca, Spain
24Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain
25Institut Català d’Oncologia, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L Hospitalet De Llobregat (barcelona), Spain
26Hematology Department., Hospital Duran i Reynals. Institut Català d'Oncologia, Hospital Duran i Reynals. Institut Català d'Oncologia, Hospitalet, BARCELONA, Spain
27Hematology and Medical Oncology Department, Hospital Morales Meseguer. Centro Regional de Hemodonación. Universidad de Murcia. IMIB, MURCIA, Murcia, Spain
28Internal Medicine Service, Hospital Universitario Morales Meseguer, Murcia, Spain
29Hematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain
30Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Imas12, Madrid, Spain
31Department of Anesthesiology, Hospital Universitario Virgen De La Arrixaca, Murcia, Spain
32Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain
33Univerisity Clinical Hospital Virgen Arrixaca, Murcia, ESP
34CIBERER (U-765), Murcia, Spain
35UCAM, Murcia, Spain

Xiaoying Zhang1*, Xingcheng Yang1*, Chunyan Wang1*, Liang Huang, MD2, Yicheng Zhang2,3 and JIA Wei, MD, PhD4*

1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
4Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, BALTIMORE, MD

Constance Baer, PhD, Wencke Walter, PhD*, Stephan Hutter, PhD*, Niroshan Nadarajah*, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD and Manja Meggendorfer, PhD

MLL Munich Leukemia Laboratory, Munich, Germany

Matilde Y Follo, PhD1*, Alessia De Stefano, BSc1*, Sara Mongiorgi, PhD1*, Valentina Indio, PhD2*, Annalisa Astolfi, PhD3*, Stefano Ratti, MD, PhD1*, Andrea Pellagatti, PhD4*, Miriam Fogli, PhD5*, Andrea Pession, MD6*, Michele Cavo, MD, PhD7*, Lucia Manzoli, MD1*, Lucio Cocco, MD1*, Jacqueline Boultwood, PhD4, Sarah Parisi, MD, PhD8, Stefania Paolini, MD, PhD5* and Carlo Finelli, MD5*

1Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
2Interdepartmental Centre of Cancer Research "G. Prodi", University of Bologna, Bologna, Italy
3Dipartimento di Morfologia, chirurgia e medicina sperimentale, University of Ferrara, Ferrara, Italy
4Blood Cancer UK, University of Oxford, Oxford, United Kingdom
5IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”, Bologna, Italy, Bologna, Italy
6IRCCS Azienda Ospedaliero-Universitaria di Bologna - Department of Pediatrics, Bologna, Italy, Bologna, Italy
7Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
8IRCCS Azienda ospedaliero-universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

*signifies non-member of ASH